rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    FDMT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      4DMT Announces New Employment Inducement Grants
      Nov 13Yahoo FinanceFDMT
      4D Molecular earnings missed by $0.03, revenue topped estimates
      Nov 12Investing.comFDMT
      4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Tops Revenue Estimates
      Nov 12Yahoo FinanceFDMT
      4D Molecular Therapeutics at guggenheim: wet amd push gains pace
      Nov 10Investing.comFDMT
      4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
      Nov 2Yahoo FinanceFDMT
      H.C. Wainwright reiterates 4D Molecular stock rating at buy
      Oct 22Investing.comFDMT
      4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
      Oct 22Yahoo FinanceFDMT
      4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day - Slideshow (NASDAQ:FDMT) 2026-10-21

      2026-10-21. The following slide deck was published by 4D Molecular Therapeutics, Inc.

      Oct 21Seeking AlphaFDMT
      4D Molecular Therapeutics Rings the Closing Bell

      About This Event4D Molecular Therapeutics (Nasdaq: FDMT), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT rings the Closing Bell.

      Oct 21NasdaqFDMT
      Scott Bizily, 4D Molecular Therapeutics CLO, sells $20,993 in stock
      Oct 21Investing.comFDMT
      4DMT Announces New Employment Inducement Grants

      EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 13, 2026, the compensation committee of the Company’s board of directors granted 13 new non-executive employees options to purchase an aggregate of 260,000 shar

      Oct 16Yahoo FinanceFDMT
      Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Pfizer (PFE) and Incyte (INCY)

      Tipranks Press Release.

      Oct 14The Globe and MailFDMTINCYPFE
      Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Viking Therapeutics (VKTX)

      Detailed price information for Viking Thera (VKTX-Q) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailFDMTVKTX
      4D molecular therapeutics CEO David Kirn sells $753k in company stock
      Oct 8Investing.comFDMT
      4D Molecular Therapeutics Insider Sold Shares Worth $753,937, According to a Recent SEC Filing
      Oct 7Yahoo FinanceFDMT
      4DMT to Host Investor Day on October 21, 2026
      Oct 5Yahoo FinanceFDMT
      B.Riley reiterates Buy on 4D Molecular stock, cites trial design
      Oct 1Investing.comFDMTRILYRILYGRILYLRILYNRILYTRILYZ
      Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Envista Holdings (NVST) and Regeneron (REGN)

      Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailFDMTNVST
      4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway
      Sep 29Seeking AlphaAMDFDMT
      This is the top biotech stock pick from B Riley Securities

      Investing.com -- B. Riley Securities reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics, citing the launch of a Phase 3 trial in diabetic macular edema and encouraging two-year data for its lead gene therapy candidate.

      Sep 29Yahoo FinanceFDMT
      BofA raises 4D Molecular Therapeutics stock price target on trial data
      Sep 29Investing.comFDMT
      4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema

      4D Molecular Therapeutics (FDMT) has enrolled the first patients in a phase 3 trial of 4D-150 in dia

      Sep 28Yahoo FinanceFDMT
      4D Molecular starts Phase 3 trial for diabetic eye disease drug
      Sep 28Investing.comFDMT
      4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

      4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating 4D-150 in a treatment-naïve DME populationUpdated 2-year data from SPECTRA Part 1 clinical trial in DME continue to demonstrate a favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction EMERYVILLE, Calif., Sept. 28, 2

      Sep 28Yahoo FinanceFDMT
      Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock
      Sep 23Investing.comFDMT
      Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)

      Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailFDMT
      4D molecular therapeutics CEO Kirn sells $811,003 in stock
      Sep 16Investing.comFDMT
      4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing

      David Kirn, Director, President and Chief Executive Officer, on September 14, 2026, sold 58,333 shar

      Sep 16Yahoo FinanceFDMT
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailFDMT
      4D Molecular Therapeutics at Morgan Stanley conference: gene therapy push
      Sep 14Investing.comFDMTMS
      Cantor Fitzgerald upgrades 4D Molecular stock rating on gene therapy outlook
      Sep 14Investing.comFDMT
      Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight From Neutral

      4D Molecular Therapeutics (FDMT) has an average rating of buy and mean price target of $28, accordin

      Sep 14Yahoo FinanceFDMT
      4DMT Announces New Employment Inducement Grants
      Sep 11Yahoo FinanceFDMT
      4D Molecular Therapeutics at cantor healthcare conference: bold AMD push
      Sep 10Investing.comFDMT
      Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176
      Sep 4Investing.comFDMT
      4DMT to Participate in Upcoming Investor Conferences

      EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September: Wells Fargo 2026 Healthcare Conference: Wednesday, September

      Aug 25Yahoo FinanceFDMT

      This is the newest page. Registered accounts read further back.